Nyxoah is trading 5.03% lower at $1.51 in pre-market; no new company-specific catalyst has been identified. - Nyxoah announced Liam Kelly’s appointment as CEO after the September 28 close; the change takes effect October 1. - The appointment supports its U.S. commercial focus following Genio’s FDA approval and launch, but does not explain the decline. - Broader pre-market indicators are mixed, so a market-wide cause is also unconfirmed.